New ADC phase 1 trial should start soon
LNCB74, a new antibody-drug conjugate, has received FDA approval to begin Phase 1 clinical trials. This drug targets the B7-H4 protein found on various cancer cells, including prostate cancer.
LNCB74, a new antibody-drug conjugate, has received FDA approval to begin Phase 1 clinical trials. This drug targets the B7-H4 protein found on various cancer cells, including prostate cancer.